Applications of Fmoc-D-3-Benzothienylalanine in Industrial Manufacturing

As an established manufacturer of Fmoc-D-3-Benzothienylalanine, we supply this noncanonical amino acid for advanced industrial applications where its unique chiral and aromatic structure enables development of high-value peptide and pharmaceutical intermediates. The following scenarios present its principal real-world downstream uses, focusing on differentiated industrial sectors, each supported by precise regulatory, compositional, and manufacturing integration details.

1. Peptide Drug Development for Oncology Research

Pharmaceutical companies employ Fmoc-D-3-Benzothienylalanine in solid-phase peptide synthesis (SPPS) when developing tumor-targeting investigational peptides and peptidomimetics. Its D-configuration and aromatic side chain introduce metabolic resilience and enhanced binding specificity in preclinical oncology drug candidates. In this setting, it is typically used during preclinical and clinical-grade API development per current ICH and pharmacopoeial standards.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• USP <797> (Pharmaceutical Compounding—Sterile Preparations)
• European Pharmacopoeia Monograph 2030
• FDA Guidance for Industry: Peptide Drug Products

Typical usage ratio

• 1–5 mol% of total amino acid sequence by residue count; actual percentage based on the number of targeted substitution sites per peptide design protocol

Downstream process integration

• Coupling during the chain elongation stage of SPPS, following standard Fmoc/tBu-protected peptide synthesis schemes on automated synthesizers

Final product types

• Investigational peptide-based oncology therapeutics (clinical trials Phase I–II)
• Preclinical anti-cancer peptide libraries
• Peptidomimetic hit-to-lead candidates for targeted therapies

2. Peptide Probe Manufacturing for Biomarker Discovery

Biotechnology and diagnostic companies integrate Fmoc-D-3-Benzothienylalanine to synthesize peptide probes with unique aromatic tags for advanced biological assays, including fluorescence quenching and binding specificity testing. This amino acid supports synthesis of D-peptide mimics with enhanced resistance to proteolysis, facilitating high-fidelity biomarker evaluation in proteomics workflows.

Industry compliance standards

• ISO 13485:2016 (Medical Devices—Quality Management)
• OECD GLP Principles (for probe evaluation in analytical labs)
• USP Chapter <1047> (Testing for Biologics and Peptides)

Typical usage ratio

• 2–8 mol% in oligopeptide sequences; percentage determined by probe design specifications and detection sensitivity requirements

Downstream process integration

• Direct introduction at selective positions during peptide microarray or combinatorial library synthesis on solid supports, prior to terminal deprotection and cleavage

Final product types

• Custom peptide biomarker probes
• Peptide microarrays for high-throughput screening
• Proteomics research kits

3. Synthesis of PROTAC Intermediates

Fmoc-D-3-Benzothienylalanine contributes as a building block for the synthesis of bifunctional chemical linkers in PROTAC (Proteolysis Targeting Chimeras) drug research. Its aromatic thienyl group provides structural diversity to linkers, influencing binding affinity and selectivity for target protein degradation constructs manufactured for early-stage pharmaceutical R&D contracts.

Industry compliance standards

• US FDA cGMP guidelines for clinical trial materials
• EMA Guidelines on Quality of Chemical Medicinal Products (EMA/CHMP/QWP/545525/2017)
• ICH Q11 (Development and Manufacture of Drug Substances)

Typical usage ratio

• 0.5–2 equivalents per bifunctional linker; adjusted to target the required physicochemical profile of the resulting PROTAC molecule

Downstream process integration

• Employed in linker conjugation steps during the fragment assembly of PROTACs via SPPS or solution-phase coupling, immediately before molecule finalization and purification

Final product types

• PROTAC linker intermediates
• Research-use-only bifunctional molecules
• Custom degrader compound libraries

4. Production of Stable Isotope-Labeled Peptides for Quantitative Mass Spectrometry

Analytical laboratories utilize Fmoc-D-3-Benzothienylalanine as a critical precursor in the synthesis of stable isotope-labeled peptides necessary for quantitative LC-MS and MALDI-MS bioanalytical assays. The D-configuration introduces spectral separation and protease stability, improving internal standard performance for pharmacokinetics and bioavailability studies.

Industry compliance standards

• ISO/IEC 17025:2017 (Testing and Calibration Laboratories)
• FDA Bioanalytical Method Validation Guidance
• European Pharmacopoeia Monograph 2.9.40 (Peptide Detection Methods)

Typical usage ratio

• ≤10 mol% substitution for specific residues within custom synthetic standards, according to the target protein segment and MS method protocol

Downstream process integration

• Fmoc-D-3-Benzothienylalanine is coupled during stepwise assembly of the labeled peptide, prior to isotopic enrichment, then released from solid support and purified for LC/ESI or MALDI analysis

Final product types

• Isotope-labeled peptide internal standards
• MS peptide calibration standards
• Customized peptides for quantitative proteomics